LENZ Therapeutics Inc LENZ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
-
These beaten-down stocks could bounce back in January, if history is any guide
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
-
LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
-
LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
Trading Information
- Previous Close Price
- $3.57
- Day Range
- $3.21–3.56
- 52-Week Range
- $3.21–39.94
- Bid/Ask
- $3.20 / $3.26
- Shares Outstanding
- 31.42M
- Market Cap
- $102.74M
- Volume/Avg
- 939,082 / 796,152
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.84
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 152
- Website
- https://www.lenz-tx.com
Valuation
|
Metric
|
LENZ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.49 |
Price/Sales | 4.84 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LENZ
|
|---|---|
Quick Ratio | 12.81 |
Current Ratio | 13.55 |
Interest Coverage | — |
Quick Ratio
LENZ
Profitability
|
Metric
|
LENZ
|
|---|---|
Return on Assets (Normalized) | −45.62% |
Return on Equity (Normalized) | −49.29% |
Return on Invested Capital (Normalized) | −52.58% |
Return on Assets
LENZ
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Cq<Z?r | LOCK|G#HW | $127B | |||
| Moderna Inc
MRNA
| LOCK|wq#^cPm | LOCK|<^ | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Nm@cxX | LOCK|%?%g | $81B | |||
| argenx SE ADR
ARGX
| LOCK|>L@ct< | LOCK|xsv | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?SM#$& | LOCK|qCQ | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%<%$%LS | LOCK|dNRgx | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%&Y!@sx | LOCK|%@zwN | $27B | |||
| Incyte Corp
INCY
| LOCK|fBXskMv | LOCK|!sp | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|&g^m$d | LOCK|TQT | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Q%Rl!h | LOCK|MF | $14B |
United States